Jessica Imrie, MBA

Jessica has more than 20 years of experience in pharmaceutical development and more than 8 years of experience working in cell and gene therapies. She started her career at Ernst & Young as a consultant for hospital networks in New Zealand, and in 2002, joined GlaxoSmithKline (GSK), where she worked across discovery and development functions in strategic and operational roles. In 2012, Jessica joined the GSK Rare Diseases Team and worked cross-functionally to help deliver ground-breaking cell and gene therapy treatments for multiple immunodeficiencies and leukodystrophies. In 2016, she led the European launch of the first autologous ex vivo gene therapy (Strimvelis) for children born with adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID), and through 2018, she led the rare growth strategy plans for cell and gene therapy treatments worldwide for GSK. Jessica also brings small biotech gene therapy experience to Interius, having led the development of 2 programs toward IND submission at Limelight Bio.

Jessica received her MBA in healthcare and pharmaceuticals from Drexel University, Philadelphia, and her undergraduate degree in strategic management and industrial psychology at the University of Waikato in New Zealand.